Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune checkpoint inhibition: from molecules to clinical application.

Literature DB >> 32297327

Immune checkpoint inhibition: from molecules to clinical application.

L S Taams¹, T D de Gruijl².

Abstract

Mesh：

Substances：

Year: 2020 PMID： 32297327 PMCID： PMC7160649 DOI： 10.1111/cei.13434

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

× No keyword cloud information.

13 in total

Review 1. Mechanisms of checkpoint inhibition-induced adverse events.

Authors: P Urwyler; I Earnshaw; M Bermudez; E Perucha; W Wu; S Ryan; L Mcdonald; S N Karagiannis; L S Taams; N Powell; A Cope; S Papa
Journal: Clin Exp Immunol Date: 2020-02-21 Impact factor: 4.330

2. Neoadjuvant therapy for melanoma: is it ready for prime time?

Authors: Beth Helmink; Jennifer A Wargo
Journal: Lancet Oncol Date: 2019-06-03 Impact factor: 41.316

3. Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

Authors: Jun Tang; Jia Xin Yu; Vanessa M Hubbard-Lucey; Svetoslav T Neftelinov; Jeffrey P Hodge; Yunqing Lin
Journal: Nat Rev Drug Discov Date: 2018-11-28 Impact factor: 84.694

4. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.

Authors: Preeti Narayan; Sakar Wahby; Jennifer J Gao; Laleh Amiri-Kordestani; Amna Ibrahim; Erik Bloomquist; Shenghui Tang; Yuan Xu; Jiang Liu; Wentao Fu; Pengfei Song; Bellinda L King-Kallimanis; Sherry Hou; Yutao Gong; Shyam Kalavar; Soma Ghosh; Reena Philip; Kirsten B Goldberg; Marc R Theoret; Gideon M Blumenthal; Paul G Kluetz; Rajeshwari Sridhara; Richard Pazdur; Julia A Beaver
Journal: Clin Cancer Res Date: 2020-01-30 Impact factor: 12.531

Review 5. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.

Authors: Z Quandt; A Young; M Anderson
Journal: Clin Exp Immunol Date: 2020-02-28 Impact factor: 4.330

Review 6. VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors: M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal: Clin Exp Immunol Date: 2020-02-04 Impact factor: 4.330

7. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors: A van Elsas; A A Hurwitz; J P Allison
Journal: J Exp Med Date: 1999-08-02 Impact factor: 14.307

Immune checkpoint inhibition: from molecules to clinical application.

Review 1. Mechanisms of checkpoint inhibition-induced adverse events.

2. Neoadjuvant therapy for melanoma: is it ready for prime time?

3. Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

4. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.

Review 5. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.

Review 6. VISTA: Coming of age as a multi-lineage immune checkpoint.

7. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

8. A new member of the immunoglobulin superfamily--CTLA-4.

Review 9. TIGIT as an emerging immune checkpoint.

10. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

1. 55 years in the life of Clinical & Experimental Immunology.

Review 2. Nucleic Acid-Based Approaches for Tumor Therapy.